Evaluating PET/CT for diagnosing Tau-related diseases

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effectiveness of 18F-92/AV45 and 11C-PIB positron emission tomography/computed tomography (PET/CT) in diagnosing primary and metastatic lesions in patients with various Tau-related diseases. Participants, who are adults with suspected or newly diagnosed malignant tumors, will undergo PET/CT scans to quantify lesion uptake using the maximum standard uptake value (SUVmax). The study will calculate key diagnostic metrics such as sensitivity, specificity, and accuracy to determine the utility of these imaging techniques.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled Aβ PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

• The First Affiliated Hospital of University of Science and Technology of China
  Hefei, Anhui, China Recruiting
• Chinese PLA General Hospital,
  Beijing, Beijing Municipality, China Recruiting
• The Affiliated Hospital of Qingdao University
  Qingdao, Shandong, China Recruiting
• Tianjin Medical University General Hospital
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Ying Wang, MD
• Email: macrossplusvoices@163.com
• Phone: +8618702292537

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registering medical data and care outcomes for ALS, SMA, and other motor disorders

  This registry slowly collects routine-care information from adults with ALS, SMA, or other motor disorders to see how they’re treated and how care affects outcomes.

  Recruiting Ambulanzpartner Soziotechnologie APST GmbH · Berlin, State of Berlin · NCT07900672

• Testing LY4405094 in healthy people and people with Alzheimer’s disease

  This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.

  Recruiting Phase 1 Eli Lilly and Company · Anaheim, California and 17 other locations · NCT07787182

• Test of amyloid-targeting medicines in healthy people and adults with Alzheimer’s

  This trial tests the safety and tolerability of amyloid-targeting drugs, plus a placebo, in healthy adults and in people with Alzheimer’s disease to see if the drugs can reduce brain amyloid plaques.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Anaheim, California and 18 other locations · NCT07787169

• Prenatal education to reduce environmental exposures during pregnancy

  Aimed at pregnant people, this program tests whether a classroom-style education can help reduce exposure to harmful pollutants from seafood and nearby pollution sources.

  Recruiting at 2 sites The University of Texas Medical Branch, Galveston · Galveston, Texas and 1 other locations · NCT07758114

• Donanemab in Early Cognitive Decline with Lewy Body Features (TRAILBLAZER-ALZ 7)

  This trial tests donanemab versus placebo to see if it can slow thinking and daily-function decline in people with early cognitive decline and Lewy body disease features.

  Recruiting at 47 sites Phase 2 Eli Lilly and Company · Chandler, Arizona and 71 other locations · NCT07589595

• Hyperspectral retinal imaging to detect Alzheimer’s and other neurodegenerative changes

  This project will test whether a special retinal camera that scans many wavelengths of light can detect signs of Alzheimer’s and other neurodegenerative diseases in people with dementia or at risk.

  Recruiting Center for Eye Research Australia · Melbourne, Victoria · NCT07545473

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.